RoActemra Articles

Roche's RoActemra shows superiority to Humira in rheumatoid arthritis

18 March 2013

FDA accepts file for new Actemra formulation in rheumatoid arthritis

28 February 2013

Roche's RoActemra beats leading rival Humira in RA study; other news from EULAR

7 June 2012

NICE backs Roche RoActemra, but with PAS discount

22 February 2012

Mixed NICE views on Faslodex and RoActemra

14 December 2011

UK’s NICE provisionally backs wider use of Roche’s RoActemra for rheumatoid arthritis

7 October 2011

UK’s NICE calls for more data on Roche’s RoActemra for sJIA

11 August 2011

Roche gets EU approval for RoActemra for children with rare form of arthritis

4 August 2011

Good news for Britain’s RA patients as NICE backs NHS use of MabThera and Humira, as well as Enbrel, Remicade, Orencia and RoActemra in some circumstances

25 August 2010

Uptake of alternative biologics such as Roche/Chugai's Actemra/RoActemra will erode RA market share of TNF-alpha inhibitors through 2019

30 July 2010

Europe’s CHMP updates on pandemic vaccines, backs use extensions for Reyataz and RoActemra, concludes Seroquel XR arbitration

26 April 2010

Showing 1-11 of 11 articles

Go to beginningPrevious
  • 1
NextGo to end